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1200Valvular 18F-Fluoride and
18F-Fluorodeoxyglucose
Uptake Predict Disease
Progression and Clinical
Outcome in Patients
With Aortic Stenosis18F-Fluoride is a positron emission tomography (PET)
radiotracer that preferentially binds to regions of
newly forming vascular microcalciﬁcations beyond
the resolution of computed tomography (CT) (1).
18F-Fluorodeoxyglucose (18F-FDG) has been widely
used to measure vascular inﬂammation (2). This is the
ﬁrst prospective longitudinal study to investigate
whether these tracers predict disease progression and
clinical outcomes in aortic stenosis.
Patients age >50 years attending the outpatient
department of the Edinburgh Heart Centre were
approached for recruitment in this prospective
cohort study alongside age- and sex-matched con-
trols, as described previously (2). PET and CT were
performed in 121 volunteers (age 72  8 years; 68%
men) with and without aortic valve disease (20
controls, 20 with aortic sclerosis, and 25 with mild,
33 with moderate, and 23 with severe aortic stenosis)
using 18F-ﬂuoride (125 MBq) and 18F-FDG (200 MBq).
Uptake in the valve was measured using the most18F-Fluoride Uptake Predicts the Progression of Calciﬁcation in
lciﬁc aortic valve disease. (Left) Baseline computed tomography (CT)
ed positron emission tomography (PET)/CT images showing increased
uptake (red/yellow areas). (Right) Repeat CT scans after 2 years
croscopic calcium (white areas) in a similar distribution to that
ke.diseased segment tissue: background ratio, based
upon averaging the mean standard uptake values in
the 2 adjacent valve slices with the highest signal,
corrected for blood-pool activity. Disease progression
was assessed at 1 and 2 years using CT aortic valve
calcium scoring and echocardiography. The primary
clinical outcome endpoint was a composite of cardio-
vascular death and aortic valve replacement.
Ninety-nine participants (81%) returned for repeat
clinical assessment and echocardiography at the
2-year time point (median 736 [interquartile range
(IQR): 722 to 760] days from enrollment). Ninety-
seven patients returned for repeat CT calcium
scoring (10 scans were uninterpretable). Aortic valve
calcium score increased by 61 (IQR: 5 to 226) AU/year,
and aortic valve mean gradient increased by
0.7 (IQR: 0.2 to 2.9) mm Hg/year. After a median of
1,526 (IQR: 1,475 to 1,615) days, 29 patients had un-
dergone aortic valve replacement, whereas 7 experi-
enced cardiovascular death.
After 2 years, new valvular calcium on CT was
visible in a similar distribution as the 18F-ﬂuoride
activity on baseline PET imaging (Figure 1). Indeed,
baseline 18F-ﬂuoride uptake correlated strongly with
the subsequent rate of progression in aortic valve
calcium score (Spearman r ¼ 0.80; p < 0.001) and with
echocardiographic measures of hemodynamic pro-
gression (mean gradient r ¼ 0.32; p ¼ 0.001). In an
exploratory analysis, 18F-ﬂuoride emerged as an in-
dependent predictor of clinical outcome after age and
sex adjustments (hazard ratio: 1.55; 95% CI: 1.33 to
1.81; p < 0.001). 18F-FDG demonstrated moderate
correlations with disease progression assessed by CT
(Spearman r ¼ 0.43; p ¼ 0.001) and echocardiography
(18F-FDG r ¼ 0.30; p ¼ 0.001) and predicted clinical
outcomes independently of age and sex (hazard ratio:
1.35; 95% CI: 1.16 to 1.58; p < 0.001).
There were strong associations between the base-
line CT valvular calcium score and rate of change in
calcium score (Spearman r ¼ 0.88; 95% CI: 0.82
to 0.92; p < 0.001). Given the degree of collinearity
between CT calcium scoring and 18F-ﬂuoride uptake
in the valve (2), assessing whether 18F-ﬂuoride uptake
provided incremental predictive information to CT
was challenging. However, in a retrospective analysis
using the regression line between the CT calcium
score and 18F-ﬂuoride uptake as a cutoff, patients
with aortic stenosis and higher than expected 18F-
ﬂuoride uptake for a given CT calcium score progressed
3 times faster than participants with lower than ex-
pected uptake (median change in calcium score 315
[IQR: 127 to 492] AU/year vs. 99 [IQR: 51 to 290]
AU/year, respectively; p ¼ 0.003) Figures 1 and 2.
When a similar analysis was performed for 18F-FDG, no
FIGURE 2 18F-Flouride Uptake for a Given CT Calcium Score
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Patients with higher than expected 18F-ﬂuoride uptake for a given CT calcium score (dots in
red above regression line) demonstrated disease progression rates 3-fold greater than those
with lower than expected uptake (dots in blue below regression line). The samewas not true
for 18F-ﬂuorodeoxyglucose. AS ¼ aortic stenosis; TBRMDS ¼most diseased segment tissue:
background ratio; 18F-NaF ¼ 18F-ﬂuoride.
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1201signiﬁcant difference was observed (median change in
calcium score: 231 [IQR: 79 to 446] AU/year vs. 124
[IQR: 61 to 321] AU/year; p ¼ 0.14). Neither tracer
offered independent prediction of clinical outcomes
after correction for CT calcium scoring, perhaps
reﬂecting the small number of events and again the
collinearity between imaging parameters.
In conclusion we demonstrated that both 18F-ﬂuo-
ride and 18F-FDG predicted disease progression and
adverse clinical outcomes in aortic stenosis. In partic-
ular, 18F-ﬂuoride provided excellent prediction of the
change in CT calcium score, appearing to be of incre-
mental value to baseline CT imaging. Larger studies are
required to conﬁrm the incremental predictive value
of PET compared with CT. However, our data would
support PET/CT as a novel method for measuring dis-
ease activity in aortic stenosis, with the ability to
predict its natural history. This may be of particular
value in studies investigating novel therapies, in
which beneﬁcial treatment effects are likely to be
detected rapidly without the need for protracted
follow-up. (Role of Active Valvular Calciﬁcation
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The Devil Is in the DetailsWe read with great interest the paper by Pant et al. (1)
regarding trends in infective endocarditis (IE) inci-
dence using the Nationwide Inpatient Sample (NIS)
database to address a nagging question that has right-
fully garnered much attention and gravity: have recent
changes in IE prophylaxis guidelines for dental pro-
cedures in this country and abroad resulted in an
increase in IE incidence caused by viridans group
streptococci (VGS)? As investigators who have previ-
ously used the NIS database (2,3), we pose 2 concerns
to Pant et al. First, they unfortunately used ICD-9-CM
codes that included enterococcal (04104) and non-
VGS (038.2 Streptococcus pneumoniae septicemia, and
